60
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer

      review-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , *
      BioMedicine
      EDP Sciences
      NSCLC, Chemotherapy, Solid tumors, Natural compounds, Surgery, Radiation

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive disease to review and possibly improve therapeutic treatment options. Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy separate or in combination are commonly used to treat lung cancer. However, these treatment types may cause different side effects, and chemotherapy-based regimens appear to have reached a therapeutic plateau. Hence, effective, better-tolerated treatments are needed to address and hopefully overcome this conundrum. Recent advances have enabled biologists to better investigate the potential use of natural compounds for the treatment or control of various cancerous diseases. For the past 30 years, natural compounds have been the pillar of chemotherapy. However, only a few compounds have been tested in cancerous patients and only partial evidence is available regarding their clinical effectiveness. Herein, we review the research on using current chemotherapy drugs and natural compounds (Wortmannin and Roscovitine, Cordyceps militaris, Resveratrol, OSU03013, Myricetin, Berberine, Antroquinonol) and the beneficial effects they have on various types of cancers including non-small cell lung cancer. Based on this literature review, we propose the use of these compounds along with chemotherapy drugs in patients with advanced and/or refractory solid tumours.

          Related collections

          Most cited references161

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer statistics, 2007.

          Each year, the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. This report considers incidence data through 2003 and mortality data through 2004. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,444,920 new cancer cases and 559,650 deaths for cancers are projected to occur in the United States in 2007. Notable trends in cancer incidence and mortality rates include stabilization of the age-standardized, delay-adjusted incidence rates for all cancers combined in men from 1995 through 2003; a continuing increase in the incidence rate by 0.3% per year in women; and a 13.6% total decrease in age-standardized cancer death rates among men and women combined between 1991 and 2004. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. While the absolute number of cancer deaths decreased for the second consecutive year in the United States (by more than 3,000 from 2003 to 2004) and much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.

            We report here that BID, a BH3 domain-containing proapoptotic Bcl2 family member, is a specific proximal substrate of Casp8 in the Fas apoptotic signaling pathway. While full-length BID is localized in cytosol, truncated BID (tBID) translocates to mitochondria and thus transduces apoptotic signals from cytoplasmic membrane to mitochondria. tBID induces first the clustering of mitochondria around the nuclei and release of cytochrome c independent of caspase activity, and then the loss of mitochondrial membrane potential, cell shrinkage, and nuclear condensation in a caspase-dependent fashion. Coexpression of BclxL inhibits all the apoptotic changes induced by tBID. Our results indicate that BID is a mediator of mitochondrial damage induced by Casp8.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pancreatic cancer.

              Substantial progress has been made in our understanding of the biology of pancreatic cancer, and advances in patients' management have also taken place. Evidence is beginning to show that screening first-degree relatives of individuals with several family members affected by pancreatic cancer can identify non-invasive precursors of this malignant disease. The incidence of and number of deaths caused by pancreatic tumours have been gradually rising, even as incidence and mortality of other common cancers have been declining. Despite developments in detection and management of pancreatic cancer, only about 4% of patients will live 5 years after diagnosis. Survival is better for those with malignant disease localised to the pancreas, because surgical resection at present offers the only chance of cure. Unfortunately, 80-85% of patients present with advanced unresectable disease. Furthermore, pancreatic cancer responds poorly to most chemotherapeutic agents. Hence, we need to understand the biological mechanisms that contribute to development and progression of pancreatic tumours. In this Seminar we will discuss the most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinoma. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Biomedicine (Taipei)
                Biomedicine (Taipei)
                bmdcn
                BioMedicine
                EDP Sciences
                2211-8020
                2211-8039
                24 November 2017
                December 2017
                : 7
                : 4 ( publisher-idID: bmdcn/2017/04 )
                : 23
                Affiliations
                [1 ] Graduate Institute of Basic Medical Science, China Medical University Taichung 404 Taiwan
                [2 ] Graduate Institute of Chinese Medical Science, China Medical University Taichung 404 Taiwan
                [3 ] Department of Biological Science and Technology, Asia University Taichung 413 Taiwan
                [4 ] Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center Taipei 114 Taiwan
                [5 ] Department of Internal Medicine, Division of Cardiology, Armed Forces Taichung General Hospital Taichung 406 Taiwan
                [6 ] Department of Chemistry, Nizam College, Osmania University Hyderabad-500001 India
                [7 ] Faculty of Applied Sciences, Ton Duc Thang University Tan Phong Ward, District 7 700000 Ho Chi Minh City Vietnam
                Author notes
                [#]

                Equally contributed.

                [* ] Corresponding author. Faculty of Applied Sciences, Ton Duc Thang University, Tan Phong Ward, District 7, 700000 Ho Chi Minh City, Vietnam. E-mail: bharath.kumar.velmurugan@ 123456tdt.edu.vn
                Article
                bmdcn2017070423 10.1051/bmdcn/2017070423
                10.1051/bmdcn/2017070423
                5682982
                29130448
                62ff75d6-64f4-439a-ae4a-5a91da250a75
                © Author(s) 2017. This article is published with open access by China Medical University

                Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.

                History
                : 28 August 2017
                : 20 September 2017
                Page count
                Figures: 1, Tables: 1, Equations: 0, References: 157, Pages: 12
                Categories
                Review Article

                nsclc,chemotherapy,solid tumors,natural compounds,surgery,radiation

                Comments

                Comment on this article